Results 181 to 190 of about 22,174 (220)
A review of the varicella vaccine in immunocompromised individuals
International Journal of Infectious Diseases, 2004 Background: Individuals with underlying cell-mediated immunodeficiency disorders are at high risk of developing severe, life-threatening illness associated with varicella-zoster virus infection.
Ana Marli Christovam Sartori
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Current Opinion in Pediatrics, 1999
A live varicella vaccine has been licensed in Japan, Korea, some European countries, and the United States. Susceptible children can receive varicella vaccine at 12 to 18 months of age, and those who lack a reliable history of chickenpox should be immunized between 11 and 12 years of age. Susceptible children 13 years of age or older should receive two
H, Kamiya, M, Ito
openaire +2 more sources
A live varicella vaccine has been licensed in Japan, Korea, some European countries, and the United States. Susceptible children can receive varicella vaccine at 12 to 18 months of age, and those who lack a reliable history of chickenpox should be immunized between 11 and 12 years of age. Susceptible children 13 years of age or older should receive two
H, Kamiya, M, Ito
openaire +2 more sources
Pediatric Clinics of North America, 2000
Varicella vaccine is safe, effective, and cost-effective in healthy children, adolescents, and adults. Breakthrough cases of MVLS are significantly milder than wild-type varicella infection. No severe adverse events have been reported following vaccination, and the incidence of herpes zoster is less in vaccinees than in individuals who have had natural
openaire +2 more sources
Varicella vaccine is safe, effective, and cost-effective in healthy children, adolescents, and adults. Breakthrough cases of MVLS are significantly milder than wild-type varicella infection. No severe adverse events have been reported following vaccination, and the incidence of herpes zoster is less in vaccinees than in individuals who have had natural
openaire +2 more sources
1990
A live varicella vaccine has been developed, and its safety and immunogenicity have been established in normal children as well as in high-risk children.
M, Takahashi +4 more
openaire +2 more sources
A live varicella vaccine has been developed, and its safety and immunogenicity have been established in normal children as well as in high-risk children.
M, Takahashi +4 more
openaire +2 more sources
Dermatologic Therapy, 2009
In the past, the varicella zoster virus affected virtually the entire population and had substantial morbidity and mortality associated with both primary varicella and herpes zoster reactivation. Since the varicella vaccine was first approved in 1995, there has been a significant decline in incidence, morbidity, and mortality caused by primary ...
Rosella, Creed +2 more
openaire +2 more sources
In the past, the varicella zoster virus affected virtually the entire population and had substantial morbidity and mortality associated with both primary varicella and herpes zoster reactivation. Since the varicella vaccine was first approved in 1995, there has been a significant decline in incidence, morbidity, and mortality caused by primary ...
Rosella, Creed +2 more
openaire +2 more sources
Varicella Vaccination in Children
BioDrugs, 2000Varicella vaccines have been developed, studied, tested and used since the early 1970s, first in Japan and subsequently in Europe, the US, Asia and South and Central America. Varicella vaccination was first used to immunise Japanese children in cancer remission, as wild-type varicella disease is often fatal in immunocompromised individuals. Since then,
openaire +2 more sources
Varicella vaccination in Australia
Journal of Paediatrics and Child Health, 2005Abstract: Varicella zoster virus (VZV) causes both chickenpox and herpes zoster and is responsible for a significant disease burden, including hospitalizations and deaths, in Australian children and adults. Varicella vaccine has been available in Australia for 5 years; however, from November 2005, it will be funded for use in all susceptible children ...
Macartney, K.M. +3 more
openaire +3 more sources
Prevention of varicella by vaccination
Journal of Hospital Infection, 1988The development, evaluation and introduction of a new vaccine is a formidable and costly task, that is only embarked on if there is an obvious need to prevent a particular disease. As chickenpox, the primary infection with Varicella zoster virus (VZV), is usually such a mild and comparatively unimportant disease, it was perhaps something of a surprise ...
openaire +2 more sources
Infectious Disease Clinics of North America, 1996
The live attenuated varicella vaccine, which is available for the prevention of chickenpox, was produced by a classic technology that also has been used for polio, measles, mumps, and rubella vaccines. There are many newer technologies that have been applied to the research and development of other vaccines.
openaire +2 more sources
The live attenuated varicella vaccine, which is available for the prevention of chickenpox, was produced by a classic technology that also has been used for polio, measles, mumps, and rubella vaccines. There are many newer technologies that have been applied to the research and development of other vaccines.
openaire +2 more sources